Skip to content

Stamaril Research

Clinical Research to Collect Safety Information Obtained Following Vaccination with Stamaril - STA00014

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031180027
Enrollment
13000
Registered
2018-10-17
Start date
2018-10-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Yellow fever Yellow fever

Interventions

Injection of Stamaril Vaccine
Yellow fever Vaccine, Stamaril

Sponsors

Ohmagari Norio
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Person who may be exposed to the risk of yellow fever 2) Person aged 9 months or older on the day of vaccination with Stamaril 3) Person who gave written consent to get vaccinated with Stamaril which is unapproved in Japan, as an alternative to Yellow Fever Vaccine. 4) For persons aged 16 to less than 20 years, written consent from their legal representative is also needed in addition to written consent from the participant. 5) For persons aged less than 16 years, written consent from their legal representative is needed. 6) For persons aged 6 months to less than 9 months, persons who are or are possibly pregnant, persons aged 60 years or older, and persons infected with asymptomatic human immunodeficiency virus not associated with immune dysfunction, their doctor should judge that the expected benefits of vaccination outweigh the risks.

Exclusion criteria

Exclusion criteria: 1) Person with hypersensitivity to any of the additives contained in Stamaril, chicken eggs, or chicken meat proteins 2) Person with congenital or acquired immunodeficiency, such as those receiving immunosuppressive therapy with chemotherapy, systemic administration of corticosteroids, etc. 3) Person with a history of thymic dysfunction (including myasthenia gravis, thymoma, and thymectomy) 4) Person infected with symptomatic human immunodeficiency virus 5) Person infected with asymptomatic human immunodeficiency virus associated with immune dysfunction 6) Person with fever (more than 37.5 degrees) 7) Person who is judged by the doctor to have severe acute disease 8) Breastfeeding women who cannot suspend breastfeeding for at least 14 days after vaccination with Stamaril 9) Other persons who are judged by their doctor to be not appropriate for getting vaccinated prophylactically

Design outcomes

Primary

MeasureTime frame
Safety reports after injection of Stamaril and spontaneous safety reports by participants

Contacts

Public ContactMugen Ujie

National Center for Global Health and Medicine

mgujiie@hosp.ncgm.go.jp+81-3-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026